ScholarIQanswers from OpenAlex & ORCID
Gregory A. Masters
ResearcherPublications, citations & collaboration network
Gregory A. Masters is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Gregory A. Masters have?
ScholarIQindexed works
Gregory A. Masters has 338 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Gregory A. Masters have?
ScholarIQcitation count
Gregory A. Masters has 16,189 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Gregory A. Masters?
ScholarIQh-index
Gregory A. Masters has an h-index of 51 in OpenAlex.
What is the i10-index of Gregory A. Masters?
ScholarIQi10-index
Gregory A. Masters has an i10-index of 86 in OpenAlex.
What is the ORCID of Gregory A. Masters?
ScholarIQorcid
The ORCID for Gregory A. Masters is on the source record.
What is the OpenAlex record for Gregory A. Masters?
ScholarIQopenalex
The OpenAlex for Gregory A. Masters is on the source record.
What are the most-cited papers on Gregory A. Masters?
ScholarIQmost cited works
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki, Gregory A. Masters, George Blumenschein, Steven E. Schild, Jeffrey A. Bogart, Chen Hu, Kenneth Forster, Anthony M. Magliocco, Vivek S. Kavadi, Yolanda I. Garces, Samir Narayan, Puneeth Iyengar, Clifford G. Robinson, Raymond B. Wynn, Christopher D. Koprowski, Joanne Meng, Jonathan J. Beitler, Rakesh Gaur, Walter J. Curran, Hak Choy
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel‐Angel Perales, Igor Puzanov, Bianca Santomasso, Satish Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients
Thomas Condamine, George A. Dominguez, Je‐In Youn, Andrew V. Kossenkov, Sridevi Mony, Kevin Alicea-Torres, Evgenii N. Tcyganov, Ayumi Hashimoto, Yulia Nefedova, Cindy Lin, Simona Partlová, Alfred L. Garfall, Dan T. Vogl, Xiaowei Xu, Stella C. Knight, George Malietzis, Gui Han Lee, Evgeniy Eruslanov, Steven Μ. Albelda, Xianwei Wang, Jawahar L. Mehta, Meenakshi Bewtra, Anil K. Rustgi, Neil Hockstein, Robert Witt, Gregory A. Masters, Brian Nam, Denis A. Smirnov, Manuel A. Sepúlveda, Dmitry I. Gabrilovich
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer
Jeffrey D. Bradley, Chen Hu, Ritsuko Komaki, Gregory A. Masters, George R. Blumenschein, Steven E. Schild, Jeffrey A. Bogart, Kenneth Forster, Anthony M. Magliocco, Vivek S. Kavadi, Samir Narayan, Puneeth Iyengar, Clifford G. Robinson, Raymond B. Wynn, Christopher D. Koprowski, Michael R. Olson, Joanne Meng, Rebecca Paulus, Walter J. Curran, Hak Choy
Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
Glenwood Goss, Chris J. O’Callaghan, Ian Lorimer, Ming‐Sound Tsao, Gregory A. Masters, James R. Jett, Martin J. Edelman, Rogério Lilenbaum, Hak Choy, Fadlo R. Khuri, Katherine M.W. Pisters, David R. Gandara, Kemp H. Kernstine, Charles Butts, Jonathan Noble, Thomas A. Hensing, Kendrith M. Rowland, Joan H. Schiller, Keyue Ding, Frances A. Shepherd